drugset / Trial / NCT01756430

Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

NCT01756430

Phase 3 Completed 238 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of present study is to evaluate the efficacy and safety of Carvedilol SR versus Carvedilol IR in Patients With Essential Hypertension

Timeline

Start
2012-12
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 25 mg
Subject Carvedilol Other / unclassified 64 mg